

DAFTAR PUSTAKA

1. Elbirt D, Guri KM, Rosenberg SB, Gill H, Attali M, Asher I. HIV- associated neurocognitive disorders (HAND). *Isr Med Assoc J.* 2015;17(1):54–9.
2. Daroff RB, Jankovic J, Mazziotta JC, Pomeroy SL. *Bradley's neurology in clinical practice.* New edition/ed. Philadelphia. 2016.
3. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. *AIDS.* 2007;21(14):1915–21.
4. Moore DJ, Letendre SL, Morris S, Umlauf A, Deutsch R, Smith DM, et al. Neurocognitive functioning in acute or early HIV infection. *J Neurovirol.* 2011;17(1):50–7.
5. Nath A. Changing pattern and pathophysiology of cognitive dysfunction with HIV infection in the era of antiretroviral therapy. *J Neurovirol.* 2011;17:1–2.
6. Iswahyudhi. Faktor-faktor yang mempengaruhi gangguan fungsi kognitif pada pasien infeksi human immunodeficiency virus (HIV) di makassar [Tesis]. Makassar : Fakultas Kedokteran Universitas Hasanuddin; 2021.
7. Souza EM, Buoniconti CS, Valim FC, Moura AS. Risk factors for neurocognitive impairment in HIV-infected patients and comparison of different screening tools. *Dement Neuropsychol.* 2016;10(1):42–6.
8. Cross S, Önen N, Gase A, Overton ET, Ances BM. Identifying risk factors for HIV-associated neurocognitive disorders using the international HIV dementia scale. *J Neuroimmune Pharmacol.* 2013;8(5):1114–22.
9. Zhang Y, Qiao L, Ding W, Wei F, Zhao Q, Wang X, et al. An initial screening for HIV-associated neurocognitive disorders of HIV-1 infected patients in China. *J Neurovirol.* 2012;18(2):1–11.
10. Estiasari R, Imran J, Lastri DN, Prawiroharjo P, Price P. Cognitive impairment among Indonesia HIV naïve patients. *Neurol Asia.* 2015;20:155–60.
11. Ku NS, Lee Y, Ahn JY, Song JE, Kim MH, Kim SB, et al. HIV-associated neurocognitive disorder in HIV-infected koreans: korean neuroaids project. *HIV Med.* 2014;15(8):470–7.

12. Joska JA, Witten J, Thomas KG, Robertson C, Crook MC, Roosa H, et al. A comparison of five brief screening tools for HIV-associated neurocognitive disorders in the usa and south africa. *AIDS Behav.* 2016;20(8):1621–31.
13. Hasbun R, Eraso1 J, Ramireddy S, Wainwright DA, Salazar L, Grimes R, et al. Screening for neurocognitive impairment in HIV individuals: the utility of the montreal cognitive assessment test. *J AIDS Clin Res.* 2012;3(10):1–11.
14. Husein N, Lumempouw S, Ramli Y, Herqutanto. Uji validitas dan reliabilitas montreal cognitive assessment versi indonesia (MoCA-Ina) untuk skringing gangguan fungsi kognitif. *Neurona.* 2010;27(4):15–22.
15. Chahyani WI, Estiasari R, Prihartono J, Ramli Y. Perbandingan sensitivitas dan spesifisitas international HIV dementia scale dan montreal cognitive assessment versi indonesia dalam penapisan gangguan kognitif pasien HIV. [Tesis]. Jakarta : Program Pendidikan Dokter Spesialis Neurologi Fakuktas Kedokteran Universitas Indonesia; 2016.
16. Haddow LJ, Floyd S, Copas A, Gilson RJC. A Systematic review of the screening accuracy of the HIV dementia scale and international HIV dementia scale. *Plos One.* 2013.
17. Almeida F, Macedo A, Trigo D, Abreu M, Guimarães M, Luís N, et al. Neurocognitive evaluation using the international HIV dementia scale (IHDS) and montreal cognitive assessment test (MoCA) in an HIV-2 population. *HIV Med.* 2021 Mar; 22(3): 212–7.
18. Force G, Ghout I, Ropers J, Carcelain G, Marigout-Outtandy D, Hahn V, et al. Improvement of HIV-associated neurocognitive disorders after antiretroviral therapy intensification: the Neuro+3 study. *J Antimicrob Chemother.* 2021;76(3):743–52.
19. Tozzi V, Balesta P, Salvatori M, Vlassi C, Liuzzi G, Giancola ML, et al. Higher CPE score improved cognition, changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. *JAIDS.* 2009;52(1):56–63.
20. Njamnshi AK, Bissek AC, Ongolo-Zogo P, Tabah EN, Lekoubou AZ, Yepnjo FN, et al. Risk factors for HIV associated neurocognitive disorders (HAND) in

- sub-saharan africa the case of yaoundé-cameroon. *J Neurol Sci.* 2009;285(1):149–53.
21. Sukarini NP, Sudewi AAR, Laksmidewi AAAP. Kadar CD4+ sebagai faktor risiko gangguan kognitif pada penderita human immunodeficiency virus pra-antiretroviral [Tesis]. Denpasar : Fakultas Kedokteran Universitas Udayana/RSUP Sanglah. 2019.
 22. Azizah N, Machin A, Hamdan M. Low CD4 level increased the risk of cognitive impairment in the HIV patient. *IJPHRD.* 2020.
 23. Hartawan. Hubungan jumlah limfosit total dan limfosit T CD4+ dengan gangguan fungsi kognitif pada pasien HIV AIDS [Tesis]. Semarang ; Fakultas Kedokteran Universitas Diponegoro. 2011.
 24. Sampepajung RD, Wuysang AD, Muis A. Hubungan antara jumlah limfosit TCD4+ dengan gangguan kognitif pada pasien terinfeksi HIV. *Neurona.* 2019;36:176–80.
 25. Gisslén M, Price RW, Andreasson U, Norgren N, Nilsson N, Hagberga H. Plasma concentration of the neurofilament light protein (NfL) is a biomarker of cns injury in HIV infection: a cross-sectional study. *EBioMedicine.* 2016:135–40.
 26. Abdulle S, Mellgren A, Brew BJ, Cinque P, Hagberg L, Price RW, et al. CSF neurofilament protein (NfL) – a marker of active HIV-related neurodegeneration. *J Neurol.* 2007;254:1026–32.
 27. Krut JJ, Mellberg T, Price RW, Hagberg L, Fuchs D, Rosengren L, et al. Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. *Plos One.* 2014;9(2):1–7.
 28. Osborn KE, Khan OA, Kresge HA, Bown CW, Liu D, Moore EE, et al. Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition. *Alzheimers Dement.* 2019;11:700–9.
 29. Anderson AM, Easley KA, Kasher N, Franklin D, Heaton RK, Zetterberg H, et al. Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy. *J Neurovirol.* 2018;24(6):695–701.

30. Haryati MR, Asmarawati TP, Hadi U. Informasi dasar HIV/AIDS. Dalam : Hidayati AN, Rosyid AN, Nugroho CW (edt). Buku manajemen HIV AIDS terkini, komprehensif dan multidisiplin. Airlangga University Press; 2019:3–21.
31. Nasronudin. Virologi HIV. Dalam : Setiati S, Alwi I, Sudoyo AW (edt). In : Buku Ajar Ilmu Penyakit Dalam. 6th Ed. Jakarta; Interna Publishing: 2014: 898–901.
32. Cornett JK, Kirn TJ. Laboratory diagnosis of HIV in adults: a review of current methods. *Clin Infect Dis*. 2013;57(5):712–8.
33. UNAIDS DATA 2023. Geneva: Joint United Nations Programme on HIV/ AIDS; 2023. Licence:CC BY-NC-SA 3.0 IGO.
34. In Danger: UNAIDS Global AIDS Update 2022. Geneva: Joint United Nations Programme on HIV/ AIDS; 2022. Licence:CC BY-NC-SA 3.0 IGO.
35. Kementerian Kesehatan Republik Indonesia Direktorat Jenderal Pencegahan dan Pengendalian Penyakit. Laporan eksekutif perkembangan HIV AIDS dan penyakit infeksi menular seksual triwulan I Tahun 2023. 2023.
36. Nelwan EJ, Wisaksana R. Gejala dan diagnosis HIV. Dalam : Setiati S, Alwi I, Sudoyo AW (edt). In : Buku Ajar Ilmu Penyakit Dalam. 6th Ed. Jakarta; Interna Publishing: 2014: 910–915.
37. Patel P, Raizes E, Broyles LN. Human immunodeficiency virus infection. In: Hunter's Tropical Medicine and Emerging Infectious Disease. Tenth Edit. Philadelphia: Elsevier; 2023:232–66.
38. Pedoman Nasional Pelayanan Kedokteran Tata Laksana HIV (PNPK-HIV 2019). Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/90/2019. 2019.
39. Djoerban Z, Djauzi S. HIV/AIDS di indonesia Dalam : Setiati S, Alwi I, Sudoyo AW (edt). In : Buku Ajar Ilmu Penyakit Dalam. 6th Ed. Jakarta ; Interna Publishing : 2014 : 887–8.
40. Sachdev PS, Blacker D, Blazer DG, Ganguli M, Jeste DV, Paulsen JS, et al. Classifying neurocognitive disorders: the DSM-5 approach. *Nat Rev Neurol*. 2014;10(11):634–42.

41. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. *Neurology*. 2007;69(18):1789–99.
42. Ku NS, Lee Y, Ahn JY, Song JE, Kim MH, Kim SB, et al. HIV-associated neurocognitive disorder in HIV-infected koreans: korean neuroaids project. *HIV Med*. 2014;15(8):470–7.
43. Bandera A, Taramasso L, Bozzi G, Muscatello A, Robinson JA, Burdo TH, et al. HIV-associated neurocognitive impairment in the modern art era: are we close to discovering reliable biomarkers in the setting of virological suppression? *Front. Aging Neurosci*. 2019;(11):1–20.
44. Saylor D, Dickens AM, Sacktor D, Haughey N, Slusher B, Pletnikov M, et al. HIV-associated neurocognitive disorder - pathogenesis and prospects for treatment. *Nat Rev Neurol*. 2016;12(4):234–48.
45. McGrath NM, Cooke GS, Mtubatuba. Frequency of and risk factors for HIV dementia in an HIV clinic in sub-saharan africa. *Neurology*. 2007;69:411–3
46. McCutchan JA, Marquie_Beck JA, FitzSimonsCA, Letendre SL, Ellis RJ, heaton RK, et al. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. *Neurology*. 2012.
47. Tumbelaka CB, Ngantung DJ, Maja J. Angka kejadian komplikasi intrakranial pada penderita HIV/AIDS yang di rawat inap di bagian neurologi RSUP prof. dr. kandou manado periode juli 2012 – juni 2013. *Ecl*. 2014;(2):1–7
48. Forton DM, Thomas HC, Murphy CA, Allshop JM, Foster GR, Main J, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease: Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. *Hepatology*. 2002;35(2):433–9.
49. Drew DA, Weiner DE, Sarnak MJ. Cognitive impairment in ckd pathophysiology, management, and prevention. *Am J Kidney Dis*. 2019;74(6):782–90.
50. Lestari E, Fikrani MR, Maryanti E. Hubungan mild cognitive impairment (MCI) dengan hipertensi menggunakan mini mental state examination (MMSE). *JIK*. 2017;9(2):99.

51. Moulignier A, Viret-Vilayphon AC, Lescure FX, Plaisier E, Salomon L, Lamirel C, et al. Microalbuminuria : a sentinel of neurocognitive impairment in HIV-infected individuals?. *J Neurol*. 2020;(267):1368–76.
52. Min JY, Ha SW, Yang SH, Kang MJ, Jeong DE, Min BK, et al . Chronic status of serum albumin and cognitive function: a retrospective cohort study. *JCM*. 2022;11(3):822.
53. Bikbov B, Soler MJ, Pešić V, Capasso G, Unwin R, Endres M, et al. Albuminuria as a risk factor for mild cognitive impairment and dementia—what is the evidence? *Nephrol Dial Transplant*. 2021;37:ii55–62.
54. Lindl KA, Marks DR, Kolson DL, Jordan-Scuitto KL. HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. *J Neuroimmune Pharmacol*. 2010;5:294–309.
55. Scutari R, Alteri C, Perno C, Svicher V, Aquaro S. The role of HIV infection in neurologic injury. *Brain Sci*. 2017;7(12):38.
56. Wenzel ED, Avdoshina V, Mocchetti I. HIV-associated neurodegeneration: exploitation of the neuronal cytoskeleton. *J Neurovirol*. 2019;25(3):301–12.
57. Liu H, Xu E, Liu J, Xiong H. Oligodendrocyte injury and pathogenesis of HIV-1-associated neurocognitive disorders. *Brain Sci*. 2016;6(3):23.
58. Mind Exchange Working Group. Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. *Clin Infect Dis*. 2013;56(7):1004–17.
59. Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. *J Int Neuropsychol Soc*. 2004;10(3):317–31.
60. Valcour VG, Paul R, Chiao S, Wendelken LA, Miller B. Screening for cognitive impairment in human immunodeficiency virus. *Clin Infect Dis*. 2011;53:836–42.
61. Yilmaz A, Blennow K, Hagberg L, Nilsson S, Price RW, Schouten J, et al. Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. *Expert Rev Mol Diagn*. 2017;17:761–70.

62. Gaetani L, Blennow K, Calabresi P, Fillippo MD, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. *J Neurol Neurosurg Psychiatry*. 2019;1–12.
63. Yuan A, Nixon RA. Neurofilament protein as biomarkers to monitor neurological diseases and the efficacy of therapies. *Front. Neurosci*. 2021;15:1–28.
64. Thebault S, Booth RA, Freedman MS. Blood neurofilament light chain: the neurologist's troponin?. *Biomedicines*. 2020:1–11.
65. Portegies P, Berger JR, editors. HIV/AIDS and the nervous system. In: Aminoff MJ, Boller F, Swaab DF. *Handbook of clinical neurology*. Philadelphia : Elsevier.2007:45–52.
66. Gafson AR, Barthélemy NR, Bomont P, Carare RO, Durham HD, Julien JP, et al. Neurofilaments: neurobiological foundations for biomarker applications. *Brain*. 2020;143(7):1975–98.
67. Simrén J, Andreasson U, Gobom J, Calvet MS, Borroni B, Gillberg C, et al. Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5–90 years. *Brain Commun*. 2022;4(4):1–8.
68. Hall JR, Johnson LA, Peterson M, Julovich D, Como T, O'Bryant SE. Relationship of neurofilament light (NfL) and cognitive performance in a sample of mexican americans with normal cognition, mild cognitive impairment and dementia. *Curr Alzheimer Res*. 2020;17(13):1214–20.
69. He L, Morley J, Aggarwal G, Nguyen A, Vellas B. Plasma neurofilament light chain is associated with cognitive decline in non-dementia older adults. *Sci Rep*. 2021.
70. Fan Z, Liu X, Liu J, Chen C, Zhou M. Neurofilament light chain as a potential biomarker in plasma for Alzheimer's Disease and mild cognitive impairment: a systematic review and a meta-analysis. *J Integr Neurosci*. 2023;22(4):85.
71. Ou YN, Hu H, Wang ZT, Xu W, Tan L, Yu JT, et al. Plasma neurofilament light as a longitudinal biomarker of neurodegeneration in Alzheimer's Disease. *Brain science advances*. 2019; 5(2) : 94–105.
72. Shim Y. Clinical application of plasma neurofilament light chain in a memory clinic : a pilot study. *Dement and neurocogn disord*. 2022;2(2):59–70.

73. Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. *Lancet*. 2014; 384: 258–71.
74. Bartlett JG, Gallant JE, Conradie FM. Medical management of HIV infection. 2008 south African edition. TheraSim, Inc. 2008 .
75. Doitsh G, Galloway NLK, Geng X, Yang Z, Monroe KM, Zepeda O, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. *Nature*. 2014;505(7484):509–14.
76. Setiati S, Harimurti K, Govinda A. Proses menua dan implikasi kliniknya. Dalam : Setiati S, Alwi I, Sudoyo AW (edt). In: *Buku Ajar Ilmu Penyakit Dalam*. 6th Ed. Jakarta; Interna Publishing: 2014: 3669–3679.
77. Alagaratnam J, Francesco DD, Zetterberg H, Heslegrave A, Toombs J, Kootstra NA, et al. Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the cobra study. *Journal of NeuroVirology*. 2022;28:54–63.
78. Morgan EE, Wood SP, Smith C, Weber E, Scott JC, Grant I. HIV neurobehavioral research program (HNRP) group (2012) lower cognitive reserve among individuals with syndromic HIV-associated neurocognitive disorders (HAND). *AIDS Behav*. 2012;16:2279–85.
79. Stern R, Silva S, Chaisson N, Evans D. Influence of cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus-1 infection. *Arch Neurol*. 1996; 53:148–53.
80. Do TC, Kerr SJ, Avihingsanon A, Suksawek S, Klungkang S, CHanngnam T, et al. HIV-associated cognitive performance and psychomotor impairment in a thai cohort on long-term cart. *Journal of Virus Eradication*. 2018; 4: 41–7.

81. Giovani G. Perbandingan kadar CD4 sebelum dan sesudah ARV minimal 6 bulan pada pasien HIV [Skripsi]. Surabaya : Fakultas Kedokteran Universitas Katolik Widya Mandala Surabaya. 2017.
82. Gebremedhin T, Aynalem M, Adem M, Geremew D, Aleka Y, Kiflie A. Dolutegravir based therapy showed CD4+ T cell count recovery and viral load suppression among ART naïve people living with HIV AIDS: a pilot evaluation. *Sci Rep.* 2024; 14(1) : 3297

